Medimetriks – Acrotech Biopharma
Medimetriks Pharmaceuticals Inc. divested exclusive US rights to MM36 (difamilast ointment)
Medimetriks Pharmaceuticals Inc. announced that it had divested exclusive US rights to MM36 (difamilast ointment) to Acrotech Biopharma LLC
Other Transactions
R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. In exchange, Huadong will make an equity investment in R2 Dermatology to fund R2’s next phase of product and market development.
San Ramon, CA
R2 Technologies is the world leader in CryoAesthetics™ medical devices. Our Glacial® platform for precision contact cooling of the skin has been shown to reduce inflammation and also brighten dark spots.
Learn More
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in Asia
High Point, NC
Tv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.
Learn More